[
    [
        {
            "time": "",
            "original_text": "半年报数据显示：复星、中国医药营收达百亿，科伦净利迅增，泰格研发投入超销售费用",
            "features": {
                "keywords": [
                    "半年报",
                    "复星",
                    "中国医药",
                    "科伦",
                    "泰格",
                    "研发投入",
                    "销售费用"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "半年报数据显示：复星、中国医药营收达百亿，科伦净利迅增，泰格研发投入超销售费用",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药中报点评：主业略超预期，股权激励护航未来三年高增长",
            "features": {
                "keywords": [
                    "泰格医药",
                    "中报",
                    "主业",
                    "股权激励",
                    "高增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药中报点评：主业略超预期，股权激励护航未来三年高增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[增持评级] 泰格医药(300347)中报点评：环比增速继续提升 全面受益创新崛起",
            "features": {
                "keywords": [
                    "增持评级",
                    "泰格医药",
                    "中报",
                    "环比增速",
                    "创新崛起"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级] 泰格医药(300347)中报点评：环比增速继续提升 全面受益创新崛起",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【西南医药朱国广团队】泰格医药（300347）业绩符合预期，期权激励保障快速增长",
            "features": {
                "keywords": [
                    "西南医药",
                    "朱国广团队",
                    "泰格医药",
                    "业绩",
                    "期权激励",
                    "快速增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【西南医药朱国广团队】泰格医药（300347）业绩符合预期，期权激励保障快速增长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[审慎增持评级] 泰格医药(300347)中报点评：业绩保持快速增长 激励计划彰显对公司未来发展信心",
            "features": {
                "keywords": [
                    "审慎增持评级",
                    "泰格医药",
                    "中报",
                    "业绩",
                    "快速增长",
                    "激励计划",
                    "未来发展信心"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[审慎增持评级] 泰格医药(300347)中报点评：业绩保持快速增长 激励计划彰显对公司未来发展信心",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级] 泰格医药(300347)中报点评：业绩符合预期 股权激励利于人才储备",
            "features": {
                "keywords": [
                    "推荐评级",
                    "泰格医药",
                    "中报",
                    "业绩",
                    "股权激励",
                    "人才储备"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级] 泰格医药(300347)中报点评：业绩符合预期 股权激励利于人才储备",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]